DrugDashboards

Proctofoam Hc

pramoxine hydrochloride hydrocortisone acetate · PRAMOXINE HYDROCHLORIDE 100 mg/10g; HYDROCORTISONE ACETATE 100 mg/10g · Aerosol, Foam · Topical · Viatris Specialty LLC

NDC 00037-6822-10 · 1 CANISTER in 1 CARTON / 10 g in 1 CANISTER · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $19.37 per gram over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$19.37per GMinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D point of sale (median)$19.16per unitnegotiated price across 239 plans — before rebates · Apr 1, 2026
  • Federal contracts pay (FSS)$115.17per package of 10GMMylan Specialty L.P. · Feb 4, 2022

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$19.16per unit
middle half $18.78$19.83 · 239 plans · Apr 1, 2026
Est. net of rebates
≈ $19.16
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
4%of plans cover it
tier 2 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 9 quarters since 2024.

NADAC price per unit

$0$10.00$20.00Feb 2015Sep 2026$19.37
44 price points · per GMSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$204.10
Reported to Texas DSHS · 2026 annual filing · Viatris Specialty LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$2.4M
11,602 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for hydrocortisone acetate and pramoxine hydrochloride (other) in the next 90 days

sole-source market · price up 5% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA086195
TE code
BX
Approval date
Jan 1, 1982
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedJan 21, 2022
    Mylan Pharmaceuticals InccGMP deficiencies
  • Class II · TerminatedMar 15, 2021
    Cardinal Health Inc.CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Manufacturers of pramoxine hydrochloride hydrocortisone acetate (Aerosol, Foam)

LabelerStrengthFirst seenLast seen
Viatris Specialty LLCPRAMOXINE HYDROCHLORIDE 100 mg/10g; HYDROCORTISONE ACETATE 100 mg/10gJul 22, 2026Sep 2, 2026
Viatris Specialty LLCHYDROCORTISONE ACETATE 100 mg/10g; PRAMOXINE HYDROCHLORIDE 100 mg/10gJul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Proctofoam Hc — NDC 00037-6822-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00037682210.

Free to cite with attribution — see how the data is put together.